Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015',

In this issue

Home Eurosurveillance Edition  2008: Volume 13/ Issue 7 Article 2
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 13, Issue 7, 14 February 2008
Rapid communications
Imported schistosomiasis in Europe: preliminary data for 2007 from TropNetEurop
  1. Berlin Center for Travel & Tropical Medicine, Berlin, Germany

Citation style for this article: Jelinek T, on behalf of the European Network on Imported Infectious Disease Surveillance (TropNetEurop) . Imported schistosomiasis in Europe: preliminary data for 2007 from TropNetEurop. Euro Surveill. 2008;13(7):pii=8038. Available online:


T Jelinek ( on behalf of the European Network on Imported Infectious Disease Surveillance (TropNetEurop)

Berlin Center for Travel & Tropical Medicine, Berlin, Germany

A preliminary analysis of sentinel surveillance data of the European Network on Imported Infectious Disease Surveillance (TropNetEurop) shows 88 cases of imported schistosomiasis for 2007 (17 cases of Schistosoma haematobium, 44 of S. mansoni, 3 of S. japonicum, and 27 unknown species, e.g. early stage, Katayama fever) [1]. Although clinical reporting data for schistosomiasis are notoriously difficult to assess due to the chronic nature of the disease and thus very long periods before diagnosis is confirmed, the analysis gives a good idea about how this infection is brought into Europe.

Reported patients with schistosomiasis are predominantly male (71.6% male, 28.4% female). Median age has declined in comparison to recent years and is now at 25 years, (32 years in 2005). The proportion of immigrants in the total patient population remains at 53% (43.6% in 2005). Main purposes of travel reported by infected Europeans were tourism (47%) and missionary/humanitarian work (29%).

Unlike in 2006, but very much like in previous years, West Africa contributed the most cases. Infections from countries outside Africa do occur, but are very rare. In 2007, most infections were reported to have been imported from Mali, Senegal, Ghana, Democratic Republic of the Congo, and Uganda.

A high percentage of patients (59%) were asymptomatic when infection established. Diagnosis has to be sought actively in those patients who have been exposed. In those with clinical complaints, symptoms were quite unspecific. Most patients complained about fever, respiratory and genitourinary symptoms. Once diagnosed, the clinical management was straightforward: the majority of patients were treated on outpatient basis. Only 8% were admitted as inpatients and kept for a median time of four days. All patients were cured with praziquantel.

In consideration that a simple and effective therapy is available, schistosomiasis should be considered for diagnostic differential diagnosis when dealing with patients who might have been exposed in areas where this disease is endemic.



  1. TropNetEurop Sentinel Surveillance Report: Schistosomiasis in 2007. Available from:


Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.